Lancet Oncology recently published an international, cross-sectional study on Health technology assessment for cancer medicines across the G7 countries and Oceania. Main author Bishal Gyawali (Queen’s University, Kingston, Canada), explained us that the findings indicate discordance in public reimbursement decisions across economically similar countries, despite overlapping HTA decision criteria.